Kythera Biopharmaceuticals Inc  

(Public, NASDAQ:KYTH)   Watch this stock  
Find more results for KYTH
49.45
+0.49 (1.00%)
Apr 20 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 48.50 - 50.30
52 week 29.50 - 56.00
Open 49.23
Vol / Avg. 387,483.00/648,338.00
Mkt cap 1.26B
P/E     -
Div/yield     -
EPS -6.10
Shares 25.69M
Beta     -
Inst. own 89%
Jun 5, 2015
KYTHERA Biopharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 11:00AM EDT - Add to calendar
May 8, 2015
Q1 2015 KYTHERA Biopharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 26, 2015
KYTHERA Biopharmaceuticals Inc Corporate Call - Outlook investor - Webcast
Mar 2, 2015
Q4 2014 KYTHERA Biopharmaceuticals Inc Earnings Release
Feb 11, 2015
KYTHERA Biopharmaceuticals Inc at Leerink Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -86.30% -97.98%
Return on average equity -139.10% -129.61%
Employees 106 -
CDP Score - -

Address

27200 Agoura Rd Ste 200
AGOURA HILLS, CA 91301-5127
United States - Map
+1-818-5874500 (Phone)
+1-818-5874591 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription products for the aesthetic medicine market. The Company�s initial focus is on the facial aesthetics market. The Company�s product candidate, ATX-101, is an injectable drug in late-stage clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. The Company�s ATX-101 treatment contours the area under the chin by destroying fat cells while leaving surrounding tissue largely unaffected. The Company�s Phase II and Phase III studies have demonstrated that ATX-101, when injected subcutaneously into the target fat deposit, reduces the localized fat deposit while leaving the surrounding tissue largely unaffected. It is an attractive non-surgical solution for the reduction of submental fat.

Officers and directors

Keith R. Leonard Jr. President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
John W. Smither Chief Financial Officer
Age: 61
Bio & Compensation  - Reuters
Jeffrey D. Webster Senior Vice President - Operations
Age: 52
Bio & Compensation  - Reuters
Keith L. Klein J.D. General Counsel
Age: 50
Bio & Compensation  - Reuters
Frederick Beddingfield III, M.D., Ph.D. Chief Medical Officer
Age: 49
Bio & Compensation  - Reuters
Hollings C. Renton III Director
Bio & Compensation  - Reuters
F. Michael Ball Independent Director
Age: 59
Bio & Compensation  - Reuters
Nathaniel E. David Ph.D. Independent Director
Age: 46
Bio & Compensation  - Reuters
Dennis M. Fenton Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
Francois Kress Independent Director
Age: 47
Bio & Compensation  - Reuters